

Vitamin D Requirements and Setting Recommendations


Elizabeth A. Yetley, Ph.D. Sr. Nutrition Research Scientist (*Retired*) Office of Dietary Supplements National Institutes of Health, USA

## Nature of Nutritional Risk




### U.S. Dietary Reference Intakes Institute of Medicine





### Step 1: Outcome (Endpoint) Identification



#### Health Outcome Identification --Ideal

- Evidence: Causal relationship
  - Nutrient intake  $\rightarrow$  outcome

#### Most protective of public health:

- Is:
  - Adequacy: Endpoint with a relatively high intake level
  - Safety: Endpoint with a relatively low intake level
- May Not Be:
  - Severity of adverse effect
  - Endpoint with the strongest evidence
- May differ by life stage group

**Possible Outcomes of Adequacy** for Consideration 2008-2010 Growth Cardiovascular health Cancer Immunological outcomes Pregnancy-related outcomes Bone health Hypertension and blood pressure Obesity

#### "Indicators" Used for 1997 DRIs – Real World

Adequacy • Infants: Human milk levels, serum 25(OH)D, linear growth, bone mass • Children and adults  $\leq$  50 y: Serum 25(OH)D <27.5 nmol/L (11ng/ml)</p> • Adults > 50 y: Serum 25(OH)D <27.5 nmol/L (11ng/ml)</p> Bone loss

Possible Endpoints of Safety for Consideration 2008-2010
Hypercalcemia and hypercalciuria
Renal stones
↑ risk of some cancers (e.g., pancreatic cancer)


#### "Indicators" Used for 1997 DRIs – Real World

Safety
 Infants:


 Retarded linear growth

 All others:

 Serum calcium >2.75 nmol/liter (11 mg/dl)



#### Step 2: Dose-Response Relationships



Challenges: Deriving Dose-Response Relationships

Measurement challenges:
Exposure = sun + diet
25(OH)D varies by assay
Studies limited in number of doses used
Time to detect many outcomes
Evidence + Scientific Judgment

#### Dose-response Relationships: Unstudied Groups

- Limited or no data for some life-stage groups – but need DRIs
  - Use scientific judgment to extrapolate from studied groups

#### Examples of 1997 U.S. AI extrapolations:

- Children 1-8 y -- data from:
  - Slightly older children
  - Different continents
- Adult males:
  - Data from women
- Lactation:
  - Data from nonlactating women

Dose-response Relationships: Unstudied Groups

Examples of 1997 ULs:

Children 1-18 yr:

Used adult UL


Pregnancy and lactation:

Used adult UL

#### 1997 DRIs

Group	Adequate Intake*
7 mon – 50 y	200 IU (5 µg)
51-70 y	400 IU (10 µg)
>70 y	600 IU (15 µg)
	Upper Limit
All persons $\geq 1$ y	2000 IU (50 µg)


\*Used AI instead of EAR/RDA because of limited information on sun exposure




#### Step 3: Intake and Status Assessments

- Meets user needs how to use the reference intake values in policy and other applications?
- What is the prevalence of intakes and 25(OH)D concentrations:
  - < DRIs for adequacy?</p>
  - > ULs for safety?
  - By life-stage group?

## Children with serum 25OHD < selected cutpoints (NH 2000-2004)





#### Step 4: Risk Characterization

#### Taking into account the:

- Prevalences for low and high intakes and 25(OH)D concentrations, and
- DRI values for adequate and safe intakes
- Across all life-stage groups
- What is the nature of the public health concerns (if any)?
- What other groups warrant special concern?
  - How to apply DRI values for special groups?


#### **Groups Warranting Special** Attention in 1997 DRIs Persons or conditions that may require intakes > AI: • Persons with $\downarrow$ skin production of Vit. D<sub>3</sub>: Older Limited sun exposure Darker skin pigmentation Use of sunscreens Conditions causing malabsorption Medications that interfere Glucocorticoids Seizure control medications

## **DRI** Applications

	Planning	Assessment
Groups	EAR or AI	EAR*
	UL	UL
Individuals	RDA or AI UL	EAR or AI UL

\*If AI is reference intake of adequacy, group status assessments can not be made.

#### **Reference Intakes for Nutrients**



#### Next Steps: U.S. DRIs for Vitamin D

<u>Current Institute of Medicine Committee</u>

- http://www.iom.edu/en/Activities/Nutrition/DRIVit DCalcium.aspx
- <u>Reviewing Vitamin D and calcium</u>

Systematic reviews:

 2007 -- Effectiveness and Safety of Vitamin D in Relation to Bone Health http://www.ahrq.gov/clinic/tp/vitadtp.htm

 2009 -- Vitamin D and Calcium: Systematic Review of Health Outcomes http://www.ahrq.gov/clinic/tp/vitadcaltp.htm

Publication date: May 2010

### Possible Outcomes: New DRIs

Confirmation of previous values

- ± confidence
- Change from AI → EAR/RDA
- Change values based on:
  - New endpoints
  - Better data on Dose-response relationships
  - New data to replace extrapolations for unstudied groups
- Some combination of the above

### **EXTRA SLIDES**

Characteristics of Nutrient Reference Values Maintenance of nutritional status Safe and adequate intakes Not: treatment Apparently healthy population Not diseased population Health promotion and disease risk reduction Primary prevention for disease risk (1 incidence) Dose-response relationships Not effect size

#### Process $\rightarrow$ Reference Intakes

Scientific Review: Qualified experts Comprehensive scientific review + Expert scientific judgment Free of vested interests: Food industry Government policy-makers Consumer advocacy groups

#### Process $\rightarrow$ Reference Intakes

No reference value: not an option Consensus regarding "essentiality" • Uncertainties  $\rightarrow$  "optimal" intakes Adverse public health consequences if no reference value Decision-making process: Systematic and transparent Document, document, document

# DRI Reference Intake Values of Adequacy: U.S.

- EAR:
  - Estimated Average Requirement
  - Meet requirements of half of healthy persons
- RDA
  - Recommended Daily Allowance
  - Meet requirements of nearly all
  - Derived from EAR
- Adequate Intake
  - Adequate Intake
  - Assumed to be adequate
  - Used when insufficient data for EAR/RDA

## DRI Reference Intake Values for Safety: U.S.

UL:

Tolerable Upper Intake Level

Highest intake likely to pose no risk